ID   MB-02
AC   CVCL_7075
SY   MB02; MBO2
DR   BTO; BTO:0004767
DR   cancercelllines; CVCL_7075
DR   Cosmic; 787449
DR   Cosmic; 924045
DR   Cosmic; 975267
DR   Cosmic; 1012052
DR   Cosmic; 1012084
DR   Cosmic; 1281325
DR   Cosmic; 1465957
DR   Cosmic; 2306216
DR   GEO; GSM743417
DR   Wikidata; Q54904079
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1954374;
RX   PubMed=9096695;
RX   PubMed=10516762;
RX   PubMed=16408098;
CC   Problematic cell line: Partially contaminated. Some stocks were contaminated by HU-3 (PubMed=10516762).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00165.
CC   Characteristics: CSF2 dependent.
CC   Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=16408098).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C7965; Adult acute megakaryoblastic leukemia
DI   ORDO; Orphanet_518; Acute megakaryoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   70Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 21
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
RX   PubMed=1954374; DOI=10.1182/blood.V78.11.2860.2860;
RA   Morgan D.A., Gumucio D.L., Brodsky I.;
RT   "Granulocyte-macrophage colony-stimulating factor-dependent growth and
RT   erythropoietin-induced differentiation of a human cell line MB-02.";
RL   Blood 78:2860-2871(1991).
RX   PubMed=9096695; DOI=10.1038/sj.leu.2400621;
RA   Drexler H.G., Zaborski M., Quentmeier H.;
RT   "Thrombopoietin supports the continuous growth of cytokine-dependent
RT   human leukemia cell lines.";
RL   Leukemia 11:541-551(1997).
RX   PubMed=10516762; DOI=10.1038/sj.leu.2401510;
RA   Drexler H.G., Dirks W.G., MacLeod R.A.F.;
RT   "False human hematopoietic cell lines: cross-contaminations and
RT   misinterpretations.";
RL   Leukemia 13:1601-1607(1999).
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).